Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytomegalovirus antigen IE2 refers to the Immediate-Early 2 (IE2) protein encoded by the major immediate-early gene region of human cytomegalovirus (HCMV). This protein is a nuclear phosphoprotein, typically with a molecular weight of approximately 86 kDa, and is one of the most abundantly expressed immediate-early proteins during HCMV infection. It is a principal transcriptional activator for HCMV early genes, and also functions as a negative autoregulator. IE2 also contributes to evasion from host defense mechanisms by interfering with interferon responses, and inducing proteasomal degradation of CD83.
IE2 acts as the principal transcriptional activator for HCMV early genes, playing an essential role in initiating viral replication and lytic infection. It also functions as a negative autoregulator by repressing its own promoter activity and that of other immediate-early genes through binding to specific DNA sequences near transcription start sites.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytomegalovirus Immediate-Early 2 protein (IE2).